James N. Kochenderfer

Author

Also Known As

J N Kochenderfer, J. Kochenderfer, J. N. Kochenderfer, J.N. Kochenderfer, James N. Kochenderfer, James Kochenderfer, James N Kochenderfer, James N. Kochenderfer, Kochenderfer, James N.

243

Publications

26.5K

Citations

H-Index

115

Concepts

All Affiliations

National Cancer Institute National Institutes of Health Center for Cancer Research National Institutes of Health Clinical Center Parsons (United States)

About

James N. Kochenderfer is an author at National Cancer Institute specializing in immunotherapy, immunology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	23	4.2K
2	Engineering	16	20	634
3	Health Sciences	8	8	3.4K
4	Social Sciences	8	8	284
5	Public Health	2	2	76

James N. Kochenderfer

105

Publications

19.8K

Citations

H-Index

Page 1

	Year	Citations
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson, The Lancet T CellsT-regulatory CellImmunologyHematologyAutoimmunity	2014	2.9K
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Noopur Raje, Jesús G. Berdeja, Yi Lin, New England Journal of Medicine	2019	1.7K
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor James N. Kochenderfer, Mark E. Dudley, Sadik H. Kassim, Journal of Clinical Oncology	2014	1.6K
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells James N. Kochenderfer, Mark E. Dudley, Steven A. Feldman, Blood	2011	1.4K
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 James N. Kochenderfer, Wyndham H. Wilson, John E. Janik, Blood	2010	1.3K
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma Jennifer N. Brudno, Irina Marić, Steven D. Hartman, Journal of Clinical Oncology	2018	778
T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma Syed Abbas Ali, Victoria Shi, Irina Marić, Blood	2016	753
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma Robert O. Carpenter, Moses O. Evbuomwan, Stefania Pittaluga, Clinical Cancer Research	2013	652
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease Jennifer N. Brudno, Robert Somerville, Victoria Shi, Journal of Clinical Oncology	2016	596
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter, Blood	2013	586

Page 1